Novavax Reports Second Quarter 2020 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Outlook Therapeutics (OTLK) halted, news pending
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
Novavax (NVAX) Tops Q2 EPS by 12c, Revenues Miss
August 10, 2020 4:33 PM EDTNovavax (NASDAQ: NVAX) reported Q2 EPS of ($0.30), $0.12 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $39.58 million.
Novavax unprecedented development activities for NVX-CoV2373 and progress continued through the second quarter, said Stanley C. Erck,... More
